Literature DB >> 30148071

TIC10/ONC201-a potential therapeutic in glioblastoma.

Georg Karpel-Massler1, Markus D Siegelin2.   

Abstract

Entities:  

Year:  2017        PMID： 30148071      PMCID： PMC6108585          DOI： 10.21037/tcr.2017.10.51

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  7 in total

1.  ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.

Authors:  Mala K Talekar; Joshua E Allen; David T Dicker; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2015-06-01       Impact factor: 4.534

2.  The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent.

Authors:  Qiangbo Zhang; Hong Wang; Lin Ran; Zongli Zhang; Runde Jiang
Journal:  Biochem Biophys Res Commun       Date:  2016-05-24       Impact factor: 3.575

3.  Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.

Authors:  Varun V Prabhu; Joshua E Allen; David T Dicker; Wafik S El-Deiry
Journal:  Cancer Res       Date:  2015-02-20       Impact factor: 12.701

4.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

5.  Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Patrick A Mayes; Luv Patel; David T Dicker; Akshal S Patel; Nathan G Dolloff; Evangelos Messaris; Kimberly A Scata; Wenge Wang; Jun-Ying Zhou; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

6.  TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.

Authors:  Georg Karpel-Massler; Maïmouna Bâ; Chang Shu; Marc-Eric Halatsch; Mike-Andrew Westhoff; Jeffrey N Bruce; Peter Canoll; Markus D Siegelin
Journal:  Oncotarget       Date:  2015-11-03

7.  A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew S Chi; Joshua E Allen; Wolfgang Oster; Patrick Y Wen; Tracy T Batchelor
Journal:  Oncotarget       Date:  2017-05-12
  7 in total
  4 in total

1.  Trametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells.

Authors:  Lin Lin; Dapeng Ding; Xiaoguang Xiao; Bing Li; Penglong Cao; Shijun Li
Journal:  J Cell Mol Med       Date:  2020-04-30       Impact factor: 5.310

Review 2.  Overcoming TRAIL Resistance for Glioblastoma Treatment.

Authors:  Longfei Deng; Xuan Zhai; Ping Liang; Hongjuan Cui
Journal:  Biomolecules       Date:  2021-04-14

3.  ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression.

Authors:  Annika Dwucet; Maximilian Pruss; Qiyu Cao; Mine Tanriover; Varun V Prabhu; Joshua E Allen; Aurelia Peraud; Mike-Andrew Westhoff; Markus D Siegelin; Christian Rainer Wirtz; Georg Karpel-Massler
Journal:  Front Cell Dev Biol       Date:  2021-11-26

4.  Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer.

Authors:  Yali Fan; Jiandong Wang; Ziwei Fang; Stuart R Pierce; Lindsay West; Allison Staley; Katherine Tucker; Yajie Yin; Wenchuan Sun; Weimin Kong; Varun Prabhu; Joshua E Allen; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.